On the public citation graph

Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action

0 signed · 191 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2021.19569openalex-snapshot
Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1002/cld.900openalex-snapshot
Association of Sarcopenia and NAFLD: An Overview
inferredcites →https://doi.org/10.1002/hep.23569openalex-snapshot
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway
inferredcites →https://doi.org/10.1002/hep.26183openalex-snapshot
Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in korean men: 5-year prospective cohort study
inferredcites →https://doi.org/10.1002/hep.27368openalex-snapshot
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
inferredcites →https://doi.org/10.1002/hep.28785openalex-snapshot
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
inferredcites →https://doi.org/10.1002/hep.29085openalex-snapshot
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
inferredcites →https://doi.org/10.1002/hep.30254openalex-snapshot
Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
inferredcites →https://doi.org/10.1002/hep.30664openalex-snapshot
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
inferredcites →https://doi.org/10.1002/hep.30782openalex-snapshot
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
inferredcites →https://doi.org/10.1002/hep.31622openalex-snapshot
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
inferredcites →https://doi.org/10.1002/hep4.1054openalex-snapshot
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep4.1195openalex-snapshot
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
inferredcites →https://doi.org/10.1002/hep4.1534openalex-snapshot
Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
inferredcites →https://doi.org/10.1002/hep4.1581openalex-snapshot
Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes
inferredcites →https://doi.org/10.1002/hep4.1625openalex-snapshot
The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States
inferredcites →https://doi.org/10.1002/hep4.1760openalex-snapshot
Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007‐2016
inferredcites →https://doi.org/10.1002/hep4.1765openalex-snapshot
Poor Awareness of Liver Disease Among Adults With NAFLD in the United States
inferredcites →https://doi.org/10.1002/hep4.1802openalex-snapshot
Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection
inferredcites →https://doi.org/10.1002/hep4.1831openalex-snapshot
Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1007/s10620-018-5326-7openalex-snapshot
Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA
inferredcites →https://doi.org/10.1007/s10620-021-07317-3openalex-snapshot
Bariatric Surgery in NAFLD
inferredcites →https://doi.org/10.1007/s12072-020-10038-wopenalex-snapshot
Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population
inferredcites →https://doi.org/10.1007/s12325-017-0556-1openalex-snapshot
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk
inferredcites →https://doi.org/10.1016/j.aohep.2023.101133openalex-snapshot
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
inferredcites →https://doi.org/10.1016/j.biochi.2017.10.019openalex-snapshot
Steatosis and NASH in type 2 diabetes
inferredcites →https://doi.org/10.1016/j.cgh.2017.04.040openalex-snapshot
Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.cgh.2019.02.024openalex-snapshot
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1016/j.cgh.2021.06.048openalex-snapshot
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.cgh.2021.10.018openalex-snapshot
The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States
inferredcites →https://doi.org/10.1016/j.cgh.2021.11.004openalex-snapshot
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry
inferredcites →https://doi.org/10.1016/j.cgh.2023.01.006openalex-snapshot
Nonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality
inferredcites →https://doi.org/10.1016/j.cgh.2023.02.013openalex-snapshot
Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis
inferredcites →https://doi.org/10.1016/j.clnu.2018.11.030openalex-snapshot
A systematic review and a dose–response meta-analysis of coffee dose and nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.compbiomed.2021.104219openalex-snapshot
A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?
inferredcites →https://doi.org/10.1016/j.diabet.2019.11.001openalex-snapshot
Socioeconomic inequalities and type 2 diabetes complications: A systematic review
inferredcites →https://doi.org/10.1016/j.diabet.2020.101215openalex-snapshot
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
inferredcites →https://doi.org/10.1016/j.diabres.2021.108984openalex-snapshot
Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial
inferredcites →https://doi.org/10.1016/j.eprac.2022.03.010openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferredcites →https://doi.org/10.1016/j.jceh.2022.12.005openalex-snapshot
The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States
inferredcites →https://doi.org/10.1016/j.jhep.2014.12.012openalex-snapshot
NAFLD: A multisystem disease
inferredcites →https://doi.org/10.1016/j.jhep.2015.02.051openalex-snapshot
Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011)
inferredcites →https://doi.org/10.1016/j.jhep.2016.06.022openalex-snapshot
Exercise in NAFLD: Just do it
inferredcites →https://doi.org/10.1016/j.jhep.2016.08.023openalex-snapshot
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
inferredcites →https://doi.org/10.1016/j.jhep.2017.07.027openalex-snapshot
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
inferredcites →https://doi.org/10.1016/j.jhep.2019.03.033openalex-snapshot
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.jhep.2019.06.021openalex-snapshot
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.jhep.2022.03.026openalex-snapshot
Impact of non-invasive biomarkers on hepatology practice: Past, present and future
inferredcites →https://doi.org/10.1016/j.jhep.2022.07.004openalex-snapshot
Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design
inferredcites →https://doi.org/10.1016/j.jhep.2023.06.003openalex-snapshot
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
inferredcites →https://doi.org/10.1016/j.jhepr.2019.10.008openalex-snapshot
Lifestyle modification in NAFLD/NASH: Facts and figures
inferredcites →https://doi.org/10.1016/j.jhepr.2020.100069openalex-snapshot
Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.jhepr.2020.100171openalex-snapshot
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.jhepr.2022.100525openalex-snapshot
The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes
inferredcites →https://doi.org/10.1016/j.metabol.2020.154455openalex-snapshot
The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.metabol.2021.154752openalex-snapshot
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes
inferredcites →https://doi.org/10.1016/j.psym.2010.12.019openalex-snapshot
Depression in Patients with Nonalcoholic Fatty Liver Disease and Chronic Viral Hepatitis B and C
inferredcites →https://doi.org/10.1016/s0140-6736(15)00803-xopenalex-snapshot
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
inferredcites →https://doi.org/10.1016/s1470-2045(22)00078-xopenalex-snapshot
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/s1542-3565(04)00014-xopenalex-snapshot
Nonalcoholic fatty liver disease in patients with type 2 diabetes
inferredcites →https://doi.org/10.1016/s2213-8587(14)70032-4openalex-snapshot
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
inferredcites →https://doi.org/10.1016/s2213-8587(22)00003-1openalex-snapshot
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
inferredcites →https://doi.org/10.1038/nrgastro.2013.41openalex-snapshot
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
inferredcites →https://doi.org/10.1038/s41395-018-0088-6openalex-snapshot
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
inferredcites →https://doi.org/10.1038/s41575-023-00800-4openalex-snapshot
Lifestyle interventions in nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1053/j.gastro.2015.04.014openalex-snapshot
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
inferredcites →https://doi.org/10.1053/j.gastro.2015.04.043openalex-snapshot
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2017.05.043openalex-snapshot
Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity
inferredcites →https://doi.org/10.1053/j.gastro.2018.04.034openalex-snapshot
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
inferredcites →https://doi.org/10.1053/j.gastro.2018.08.024openalex-snapshot
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2020.01.043openalex-snapshot
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.1053/j.gastro.2020.01.051openalex-snapshot
Therapeutic Landscape for NAFLD in 2020
inferredcites →https://doi.org/10.1053/j.gastro.2020.07.050openalex-snapshot
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis
inferredcites →https://doi.org/10.1053/j.gastro.2021.07.049openalex-snapshot
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1056/nejmoa2029349openalex-snapshot
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1093/ajcn/nqaa380openalex-snapshot
Soft drink consumption and risk of nonalcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) cohort study
inferredcites →https://doi.org/10.1093/aje/kwaa206openalex-snapshot
Neighborhood Deprivation, Obesity, and Diabetes in Residents of the US Gulf Coast
inferredcites →https://doi.org/10.1097/hc9.0000000000000251openalex-snapshot
The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
inferredcites →https://doi.org/10.1097/hco.0000000000000097openalex-snapshot
The talk test
inferredcites →https://doi.org/10.1097/hep.0000000000000004openalex-snapshot
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
inferredcites →https://doi.org/10.1097/hep.0000000000000520openalex-snapshot
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
inferredcites →https://doi.org/10.1097/md.0000000000010214openalex-snapshot
Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
inferredcites →https://doi.org/10.1111/apt.12038openalex-snapshot
Non‐alcoholic fatty liver disease ( NAFLD ) is associated with low level of physical activity: a population‐based study
inferredcites →https://doi.org/10.1111/apt.14937openalex-snapshot
Systematic review with meta‐analysis: risk of hepatocellular carcinoma in non‐alcoholic steatohepatitis without cirrhosis compared to other liver diseases
inferredcites →https://doi.org/10.1111/apt.15679openalex-snapshot
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data
inferredcites →https://doi.org/10.1111/apt.16016openalex-snapshot
Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease
inferredcites →https://doi.org/10.1111/dom.14484openalex-snapshot
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
inferredcites →https://doi.org/10.1111/joim.13203openalex-snapshot
Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD
inferredcites →https://doi.org/10.1111/liv.12770openalex-snapshot
Effect of pretransplant diabetes on short‐term outcomes after liver transplantation: A National cohort study
inferredcites →https://doi.org/10.1111/liv.14354openalex-snapshot
New drugs for non‐alcoholic steatohepatitis
inferredcites →https://doi.org/10.1111/liv.14844openalex-snapshot
New drugs for NASH
inferredcites →https://doi.org/10.1111/liv.15335openalex-snapshot
One size does not fit all; practical, personal tailoring of the diet to NAFLD patients
inferredcites →https://doi.org/10.1111/liv.15437openalex-snapshot
The impact of fatigue on mortality of patients with non‐alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005–2010 and 2017–2018
inferredcites →https://doi.org/10.1136/gutjnl-2017-313884openalex-snapshot
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
inferredcites →https://doi.org/10.1136/gutjnl-2020-323106openalex-snapshot
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial
inferredcites →https://doi.org/10.1136/jim-2017-000554openalex-snapshot
Glucagon like Peptide-1 Receptor Agonists for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: A Novel Therapeutic Option
inferredcites →https://doi.org/10.1177/2042018819888824openalex-snapshot
Reduced physical activity in young and older adults: metabolic and musculoskeletal implications
inferredcites →https://doi.org/10.1186/1471-230x-14-166openalex-snapshot
Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease
inferredcites →https://doi.org/10.1186/s12893-021-01296-yopenalex-snapshot
Bariatric surgery for non-alcoholic fatty liver disease in individuals with obesity (Base-NAFLD): protocol of a prospective multicenter observational follow-up study
inferredcites →https://doi.org/10.1371/journal.pone.0050117openalex-snapshot
Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
inferredcites →https://doi.org/10.14309/ctg.0000000000000040openalex-snapshot
Serum Soluble Receptor for AGE (sRAGE) Levels Are Associated With Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.2174/1381612825666190117114305openalex-snapshot
The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.2196/11250openalex-snapshot
Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study
inferredcites →https://doi.org/10.2196/30239openalex-snapshot
Utilization of a Directly Supervised Telehealth-Based Exercise Training Program in Patients With Nonalcoholic Steatohepatitis: Feasibility Study
inferredcites →https://doi.org/10.2337/dc19-1113openalex-snapshot
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
inferredcites →https://doi.org/10.26582/k.49.1.15openalex-snapshot
The physiological mechanism behind the talk test
inferredcites →https://doi.org/10.3109/07853890.2010.518623openalex-snapshot
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity
inferredcites →https://doi.org/10.3389/fendo.2022.1087260openalex-snapshot
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
inferredcites →https://doi.org/10.3390/jcm12051852openalex-snapshot
What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
inferredcites →https://doi.org/10.3390/nu5051544openalex-snapshot
Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
inferredcites →https://doi.org/10.3748/wjg.v26.i28.4018openalex-snapshot
Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge
inferredcites →https://doi.org/10.4254/wjh.v14.i3.612openalex-snapshot
Interrelationship between physical activity and depression in nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.7573/dic.212607openalex-snapshot
Management of type 2 diabetes: consensus of diabetes organizations

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extracted
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.1002/hsr2.70920openalex-snapshot
Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)
inferred← citeshttps://doi.org/10.1007/978-3-032-18203-6_8openalex-snapshot
Menopause Transition: The Interaction Between Weight Gain, Cardiovascular Disease Risk, and Lifestyle
inferred← citeshttps://doi.org/10.1007/s00210-025-04752-1openalex-snapshot
Targeting metabolic dysfunction-associated steatotic liver disease with phytosomal silymarin and piperine: A natural alternative to fenofibrate in a rat model
inferred← citeshttps://doi.org/10.1007/s10238-026-02234-zopenalex-snapshot
Identification of circadian rhythm-associated key genes in metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.1007/s12011-025-04859-9openalex-snapshot
Serum Levels of Trace Elements and Minerals in Non-alcoholic Fatty Liver Disease Patients with and without Type 2 Diabetes are Associated with Metabolic Risk Markers
inferred← citeshttps://doi.org/10.1007/s12013-025-01881-5openalex-snapshot
One-carbon Metabolism and Epigenetic Elements are Modulated by miR-1914-5p in an in Vitro Model of Steatosis
inferred← citeshttps://doi.org/10.1007/s13679-025-00673-5openalex-snapshot
Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum
inferred← citeshttps://doi.org/10.1007/s43188-025-00326-8openalex-snapshot
Artificial intelligence‑based quantitative analysis of hepatic fibrosis in carbon tetrachloride-induced mouse model of metabolic dysfunction-associated steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.ajg.2025.01.004openalex-snapshot
“Evaluation of Curcuma zedoaria Rosc. in the management of non-alcoholic fatty liver Disease: A Randomized, single blind, controlled trial”
inferred← citeshttps://doi.org/10.1016/j.ajmo.2026.100144openalex-snapshot
Accuracy of Ultrasound for Fatty Liver Assessment
inferred← citeshttps://doi.org/10.1016/j.aohep.2026.102197openalex-snapshot
Long-term systemic effects of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/MAFLD) in children: a systematic review of persistence and progression into adulthood
inferred← citeshttps://doi.org/10.1016/j.clnu.2025.05.013openalex-snapshot
Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.dld.2026.04.011openalex-snapshot
Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age
inferred← citeshttps://doi.org/10.1016/j.etap.2025.104903openalex-snapshot
Assessing the effects of uracil-based pesticides on hepatic metabolic dysfunctions in low-cost three-dimensional multicellular spheroids
inferred← citeshttps://doi.org/10.1016/j.intimp.2025.115852openalex-snapshot
AGK2 and nicotinamide riboside reveal SIRT2's protective role in a diabetic–dietary rat model of NASH via deacetylation of NLRP3, LKB1, and FOXO3a and restoration of AMPK–ACC/PGC-1α–Nrf2 signaling
inferred← citeshttps://doi.org/10.1016/j.jff.2026.107240openalex-snapshot
Functional foods and dietary matrices for metabolic improvement: an integrative review of mechanisms, evidence, and future directions
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.12.045openalex-snapshot
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
inferred← citeshttps://doi.org/10.1016/j.metop.2024.100325openalex-snapshot
Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
inferred← citeshttps://doi.org/10.1016/j.ppedcard.2024.101775openalex-snapshot
Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease
inferred← citeshttps://doi.org/10.1016/j.psj.2024.104382openalex-snapshot
OTUD1 regulates cytokine expression and related pathways in goose fatty liver by promoting deubiquitination of its target proteins
inferred← citeshttps://doi.org/10.1016/j.tem.2024.12.006openalex-snapshot
The growing range of complications of diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.xcrm.2024.101714openalex-snapshot
Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD
inferred← citeshttps://doi.org/10.1038/s41419-025-08294-5openalex-snapshot
BRUCE liver-KO enhances MASLD/MASH development in the steatotic PTEN-KO background by impairing mitochondrial metabolism and activating STAT3
inferred← citeshttps://doi.org/10.1038/s41569-025-01220-4openalex-snapshot
The global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges
inferred← citeshttps://doi.org/10.1038/s41598-026-47839-2openalex-snapshot
PNPLA3-I148M reduces hepatic triacylglycerol secretion and mitigates diet induced left ventricular diastolic dysfunction
inferred← citeshttps://doi.org/10.1080/14737159.2026.2663523openalex-snapshot
Association between the uric acid-to-HDL-cholesterol ratio and diabetic kidney disease in individuals with type 2 diabetes and NAFLD: evidence from NHANES and an external hospital cohort
inferred← citeshttps://doi.org/10.1097/jxx.0000000000001263openalex-snapshot
A nurse practitioner's guide to metabolic dysfunction‑associated steatotic liver disease: From diagnosis to management
inferred← citeshttps://doi.org/10.1101/2024.09.13.611500openalex-snapshot
BRUCE liver-deficiency potentiates MASLD/MASH in PTEN liver-deficient background by impairment of mitochondrial metabolism in hepatocytes and activation of STAT3 signaling in hepatic stellate cells
inferred← citeshttps://doi.org/10.1101/2025.04.24.650494openalex-snapshot
PNPLA3 I148M Reduces Hepatic Triacylglycerol Secretion and Mitigates Left Ventricular Diastolic Dysfunction in MASH Diet Mice
inferred← citeshttps://doi.org/10.1111/1742-6723.70310openalex-snapshot
Epidemiology of Patients With Chronic Liver Disease Presenting to Emergency Departments in Australia
inferred← citeshttps://doi.org/10.1111/liv.70225openalex-snapshot
Metabolic Dysfunction–Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel
inferred← citeshttps://doi.org/10.1113/jp287928openalex-snapshot
Prediabetic cardiomyopathy is attenuated by hypothalamic PVN oxytocin neuron activation
inferred← citeshttps://doi.org/10.11648/j.ijg.20261001.16openalex-snapshot
The Prevalence of Steatohepatitis Declines with Age in Non-urban Individuals with Obesity
inferred← citeshttps://doi.org/10.1177/15598276261449749openalex-snapshot
Interrelationship Between Depression, Unhealthy Behavior, and Non-Alcoholic Fatty Liver Disease in the United States of America
inferred← citeshttps://doi.org/10.1186/s12876-025-04006-7openalex-snapshot
Relative fat mass and risk of metabolic dysfunction associated steatotic liver disease and severe hepatic steatosis in U.S. adults: analysis of NHANES 2017–2020 data
inferred← citeshttps://doi.org/10.1186/s12912-026-04662-4openalex-snapshot
Effect of nurse-led phlebotomy on iron stores, insulin resistance, and blood lipids: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s12944-025-02742-zopenalex-snapshot
Evaluation of a new TyG indicator, TyHGB, in predicting non-alcoholic fatty liver disease: evidence from two independent populations
inferred← citeshttps://doi.org/10.1186/s13098-024-01472-zopenalex-snapshot
The nonlinear connection between relative fat mass and non-alcoholic fatty liver disease in the Japanese population: an analysis based on data from a cross-sectional study
inferred← citeshttps://doi.org/10.1186/s41043-025-00745-1openalex-snapshot
Association between cardiovascular health and metabolic dysfunction-associated steatotic liver disease: a nationwide cross-sectional study
inferred← citeshttps://doi.org/10.1208/s12248-025-01195-7openalex-snapshot
Virtual Twin-PBPK Modelling: A Step Toward Precision Dosing in Patients with Obesity
inferred← citeshttps://doi.org/10.12968/indn.2025.7.18openalex-snapshot
Type 2 diabetes and NAFLD part 1: classification and investigations
inferred← citeshttps://doi.org/10.1371/journal.pone.0313185openalex-snapshot
Inhibition of the miR-1914-5p increases the oxidative metabolism in cellular model of steatosis by modulating the Sirt1-PGC-1α pathway and systemic cellular activity
inferred← citeshttps://doi.org/10.1515/biol-2025-1255openalex-snapshot
Flaxseed oil and probiotics protect against induced nonalcoholic fatty liver disease (NAFLD) in male rats
inferred← citeshttps://doi.org/10.1590/1519-6984.304026openalex-snapshot
Medicinal plants for treatment of fatty liver disease: an evaluation of popular knowledge based on scientific literature
inferred← citeshttps://doi.org/10.17816/mechnikov694188openalex-snapshot
Ultrasonic characteristics of liver tissue in patients receiving chemotherapy and hormone therapy for breast cancer
inferred← citeshttps://doi.org/10.21203/rs.3.rs-8607418/v1openalex-snapshot
Comparative efficacy of SGLT2 Inhibitors and Obeticholic Acid in MAFLD and Fibrosis: A Systematic Review
inferred← citeshttps://doi.org/10.22416/1382-4376-2025-35-1-94-152openalex-snapshot
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive…
inferred← citeshttps://doi.org/10.2337/dci24-0094openalex-snapshot
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
inferred← citeshttps://doi.org/10.2337/dsi23-0014openalex-snapshot
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know
inferred← citeshttps://doi.org/10.2337/dsi23-0015openalex-snapshot
Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action
inferred← citeshttps://doi.org/10.26442/20751753.2025.10.203461openalex-snapshot
Features of the development and treatment of lipid metabolism disorders in patients with metabolic dysfunction-associated steatotic liver disease: A review
inferred← citeshttps://doi.org/10.3389/fendo.2025.1693123openalex-snapshot
The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what’s different?
inferred← citeshttps://doi.org/10.3389/fendo.2026.1744741openalex-snapshot
Protective role of aqueous Coriandrum sativum seed extract in diet-induced glucolipid metabolic disorder through gut–liver axis regulation
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1627433openalex-snapshot
Regulation of hepatic Sirt1 expression and lipid metabolism through TNF receptor signaling
inferred← citeshttps://doi.org/10.3390/biomedicines13092250openalex-snapshot
Sex-Stratified Prediction Models for 5-Year Nonalcoholic Fatty Liver Disease Risk in Thyroid Cancer Patients: A Nationwide Cohort Study
inferred← citeshttps://doi.org/10.3390/cimb48020178openalex-snapshot
From Adipose Dysfunction to Multi-Organ Steatosis: Defining the Metabolic Steatotic Axis
inferred← citeshttps://doi.org/10.3390/diagnostics14222500openalex-snapshot
Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis
inferred← citeshttps://doi.org/10.3390/ijms26115057openalex-snapshot
Flexible Parametric Survival Modeling of Transaminases as Predictive Biomarkers for Non-Alcoholic Fatty Liver Disease: A Retrospective Longitudinal Study (2012–2022)
inferred← citeshttps://doi.org/10.3390/ijms26168081openalex-snapshot
Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention
inferred← citeshttps://doi.org/10.3390/jcm14061978openalex-snapshot
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
inferred← citeshttps://doi.org/10.3390/nu17040610openalex-snapshot
Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH
inferred← citeshttps://doi.org/10.3390/nu17243940openalex-snapshot
Refining MASLD Phenotypes: Clinical, Metabolic, and Elastographic Differences Between Adipose Tissue Dysfunction and Obesity-Driven Disease
inferred← citeshttps://doi.org/10.3390/nu18071087openalex-snapshot
Dietary Patterns, Hepatic Fat Fraction, and the Role of Genotype
inferred← citeshttps://doi.org/10.36290/vnl.2026.047openalex-snapshot
MASLD and its lean phenotype
inferred← citeshttps://doi.org/10.4093/dmj.2024.0641openalex-snapshot
Metabolic Dysfunction-Associated Steatotic Liver Disease and Risk of Hepatocellular Carcinoma in Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.4292/wjgpt.v17.i2.118130openalex-snapshot
Metabolic dysfunction–associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes
inferred← citeshttps://doi.org/10.52420/umj.24.2.7openalex-snapshot
Dentistry Status Features of Patients with Non-alcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.57264/cer-2026-0092openalex-snapshot
Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany
inferred← citeshttps://doi.org/10.5772/intechopen.1011551openalex-snapshot
Perspective Chapter: Targeting PTP1B for the Treatment of Steatosis – Insights from Viscosol’s Role in Insulin-Mediated Lipid Metabolism Regulation
inferred← citeshttps://doi.org/10.5812/jjnpp-159457openalex-snapshot
Does Vitamin D Independently Lower the Severity of Nonalcoholic Fatty Liver Disease? A Case-Control Study in Khuzestan Province, Iran
inferred← citeshttps://doi.org/10.58495/10.2001/journal.2026/25openalex-snapshot
Metabolic dysfunctionassociated steatotic liver disease in diabetes
inferred← citeshttps://doi.org/10.62751/2713-0177-2026-7-1-08openalex-snapshot
Non-alcoholic fatty liver disease in people with impaired glucose tolerance and type 2 diabetes mellitus: Modern approaches to therapy
inferred← citeshttps://doi.org/10.64898/2025.12.12.693988openalex-snapshot
Phenotypic Screening Coupled with AI-Driven Target Deconvolution Identifies α-Terthienyl as a Dual DPP-IV/HSD17β13 Modulator with Efficacy in a Mouse Model of MASLD
inferred← citeshttps://doi.org/10.71017/djmi.3.05.d-0282openalex-snapshot
Study on Risk Factors of Non Alcoholic Fatty Liver Disease in Patients Attending NGMCTH
inferred← citeshttps://doi.org/10.7759/cureus.103284openalex-snapshot
Liver Biopsy in Metabolic-Associated Steatotic Liver Disease: Accuracy, Challenges, and Alternatives
inferred← citeshttps://doi.org/10.7759/cureus.114542openalex-snapshot
Awareness of Non-alcoholic Fatty Liver Disease in Makkah, Saudi Arabia: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.7759/cureus.71730openalex-snapshot
Metformin: Beyond Type 2 Diabetes Mellitus
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.